Related Experiment Videos

Are MAO-A deficiency states in the general population and in putative high-risk populations highly uncommon?

D L Murphy1, K Sims, G Eisenhofer

  • 1Laboratory of Clinical Science, National Institute of Mental Health, NIH, Bethesda, MD, USA.

Journal of Neural Transmission. Supplementum
|June 13, 1998
PubMed

Insights

Monoamine oxidase A (MAO-A) deficiency, linked to cognitive and behavioral changes, is extremely rare. Early serotonin reduction in mice improved behavior, suggesting potential human therapeutic avenues.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Monoamine oxidase A (MAO-A) deficiency, caused by genetic alterations, affects monoamine metabolism.
  • This deficiency is linked to cognitive deficits and behavioral changes in humans and mice.
  • Therapeutic strategies involving serotonin synthesis reduction show promise in animal models.

Purpose of the Study:

  • To investigate the prevalence of MAO-A deficiency states in the general population and high-risk groups.
  • To explore potential therapeutic interventions for MAO deficiency.

Main Methods:

  • Screening of several hundred volunteers from the general and high-risk populations.
  • Utilizing a sequential research design to identify individuals with MAO deficiency states.

Main Results:

  • Preliminary findings indicate that marked MAO-A deficiency states are very rare.
  • Distinct symptoms, such as blindness, are associated with MAO-A deficiency linked to Xp chromosomal deletions and the Norrie disease gene.

Conclusions:

  • Marked MAO-A deficiency states are exceptionally uncommon in the studied populations.
  • Further research is warranted to understand the behavioral phenotype and explore therapeutic options for individuals with MAO deficiency.

Related Concept Videos